OBIO CAAP Company: Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.
Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.